NEOS Investment Management LLC Boosts Holdings in Medtronic PLC $MDT

NEOS Investment Management LLC boosted its holdings in shares of Medtronic PLC (NYSE:MDT) by 9.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 210,315 shares of the medical technology company’s stock after buying an additional 18,653 shares during the quarter. NEOS Investment Management LLC’s holdings in Medtronic were worth $16,453,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. AXQ Capital LP raised its position in Medtronic by 109.9% in the second quarter. AXQ Capital LP now owns 28,303 shares of the medical technology company’s stock worth $2,214,000 after acquiring an additional 14,816 shares during the period. Athena Investment Management purchased a new stake in shares of Medtronic in the 2nd quarter worth $368,000. Strengthening Families & Communities LLC increased its stake in shares of Medtronic by 7.1% in the 2nd quarter. Strengthening Families & Communities LLC now owns 26,749 shares of the medical technology company’s stock worth $2,093,000 after purchasing an additional 1,766 shares in the last quarter. Waycross Investment Management Co bought a new position in Medtronic in the 2nd quarter worth $1,109,000. Finally, Tranquilli Financial Advisor LLC raised its holdings in Medtronic by 37.6% in the 2nd quarter. Tranquilli Financial Advisor LLC now owns 9,712 shares of the medical technology company’s stock worth $760,000 after purchasing an additional 2,655 shares during the period. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Stock Up 1.1%

Shares of MDT opened at $94.12 on Friday. The business’s 50 day moving average is $86.78 and its 200 day moving average is $85.37. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a market capitalization of $120.47 billion, a PE ratio of 23.18, a price-to-earnings-growth ratio of 2.18 and a beta of 0.56.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.89% and a net margin of 13.93%.The business had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. During the same period in the prior year, the company posted $1.26 EPS. The firm’s revenue for the quarter was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Research analysts expect that Medtronic PLC will post 5.96 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Investors of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.1%. Medtronic’s dividend payout ratio is currently 70.94%.

Analyst Ratings Changes

MDT has been the subject of several recent research reports. Needham & Company LLC boosted their price target on Medtronic from $101.00 to $114.00 and gave the company a “buy” rating in a report on Thursday, August 27th. Rothschild & Co Redburn cut their price objective on Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research note on Friday, June 5th. Evercore set a $105.00 target price on shares of Medtronic in a research note on Monday, July 6th. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Monday, August 10th. Finally, Wells Fargo & Company upped their price target on shares of Medtronic from $102.00 to $104.00 and gave the stock an “overweight” rating in a research report on Wednesday. Nineteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $103.92.

Insiders Place Their Bets

In related news, EVP Harry Kiil sold 4,189 shares of the firm’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.27% of the company’s stock.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic said executives will present at the Wells Fargo Healthcare Conference on September 8 and other upcoming investor events. These appearances could provide additional updates on growth initiatives, product launches, and financial guidance. Medtronic executives to speak at upcoming investor conferences
• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating, while Stifel Nicolaus, Robert W. Baird, TD Cowen, and BTIG Research maintained bullish assessments or projected meaningful price appreciation. The broad analyst support reinforces investor confidence in MDT’s outlook. Royal Bank of Canada reaffirms Outperform rating
• Positive Sentiment: New real-world evidence from Medtronic’s PERSIST addendum study is supporting the company’s Inceptiv spinal cord stimulation system. Further clinical validation could improve adoption prospects and strengthen the pain-management franchise. Medtronic’s PERSIST study builds real-world evidence
• Positive Sentiment: Medtronic’s latest reported quarter exceeded expectations, with earnings of $1.45 per share versus a $1.39 consensus estimate and revenue of $9.76 billion versus $9.55 billion expected. Revenue increased 13.7% year over year, providing a favorable fundamental backdrop.
• Neutral Sentiment: Unusually large options trading indicates elevated investor interest in MDT, but the activity does not by itself establish whether traders expect further gains or a pullback. Medtronic target of unusually large options trading
• Negative Sentiment: A MarketWatch strategy highlighted Medtronic as a healthcare stock that may be overcrowded, recommending a bearish options position because many investors have already bet on additional gains. This raises the risk of profit-taking or volatility despite the positive fundamental and analyst backdrop. Healthcare stocks may be too crowded to own

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).